Fuse Medical Stock Price, News & Analysis

Fuse Medical, an emerging medical device manufacturer, reported a 41% increase in net revenues to $5.7 million for the quarter ended June 30, 2021, compared to $4.0 million a year prior. The company's gross profit rose 56% to $3.4 million, reflecting 61% of revenues. Despite a rise in SG&A expenses to $2.0 million, net loss improved by 80% to $85,481. CEO Christopher Reeg noted strategic initiatives, including product expansion and a successful launch of the Orbitum™ Compression Staple System, are expected to enhance growth.

Fuse Medical, Inc. (FZMD) reported its Q1 2021 results, revealing net revenues of $4.4 million, slightly down from $4.6 million in Q1 2020. Gross profit for the quarter was $2.6 million, representing 58% of revenues. SG&A expenses decreased by 42% to $1.4 million, while commissions rose by 12% to $1.6 million. The net loss narrowed significantly to $453,323, a 65% improvement from the previous year. The company launched new products, entered the Australian market, and signed several distribution agreements, while navigating pandemic-related challenges.

Fuse Medical, Inc. (OTCPINK: FZMD) filed its annual report on Form 10-K for the year ending December 31, 2020, revealing a revenue decline of approximately 6%, totaling $21.4 million. Despite the pandemic's impact, gross profit increased by about 10%, reaching $12.7 million, reflecting a gross profit margin of 59%. Operating expenses were reduced by 23% to $6.5 million, aiding in a 57% decrease in net loss, now at $1.4 million. The company launched new products and expanded its distributor network, positioning itself for growth in 2021.

Fuse Medical, Inc. (OTCPINK: FZMD) has entered an agreement with Orthovestments, LLC for the exclusive manufacturing and commercialization of the Orbitum™ Staple System in the US. This innovative device is designed for use in foot and hand surgeries, improving bone compression compared to traditional staples. The initial launch is expected in Q2 2021. The Orbitum™ features a unique titanium alloy design that enhances surface area and pull-out resistance, streamlining surgical procedures. CEO Christopher C. Reeg expressed optimism about its potential to improve surgical outcomes.

Fuse Medical, Inc. (OTCPINK: FZMD) announced a partnership with CarePICS, expanding its innovative medical devices portfolio focused on wound care. CarePICS is an app-based telehealth platform that facilitates wound care management through consultations and automated supply ordering. CEO Christopher C. Reeg emphasizes the importance of telemedicine in providing patient safety and reimbursement intelligence amid ongoing pandemic challenges. The partnership aims to enhance patient outcomes by leveraging advanced technology in clinical practices.

Fuse Medical, Inc. (OTCPINK: FZMD) announced the launch of the FuseChoice^TM line, including innovative amniotic and umbilical membranes and a joint cushioning fluid. These products serve as anatomical barriers and offer advanced treatment options for surgical intervention. CEO Christopher C. Reeg highlighted the commitment to expanding their biologics and regenerative medicine portfolio, aiming to enhance surgical outcomes. Future products such as FuseChoice Derm^TM and FusePure^TM are expected in 2021, reinforcing the company's focus on effective clinical solutions.